746 related articles for article (PubMed ID: 25406306)
1. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
2. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV; Desai AS; Givertz MM
J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
[TBL] [Abstract][Full Text] [Related]
3. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Campbell RT; Jhund PS; Castagno D; Hawkins NM; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2012 Dec; 60(23):2349-56. PubMed ID: 23141494
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
[TBL] [Abstract][Full Text] [Related]
5. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
[TBL] [Abstract][Full Text] [Related]
7. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
Badar AA; Perez-Moreno AC; Hawkins NM; Brunton AP; Jhund PS; Wong CM; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Gardner RS; Petrie MC; McMurray JJ
Eur J Heart Fail; 2015 Feb; 17(2):196-204. PubMed ID: 25678097
[TBL] [Abstract][Full Text] [Related]
10. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
[TBL] [Abstract][Full Text] [Related]
11. Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.
Miller AB; Piña IL
Congest Heart Fail; 2009; 15(4):186-92. PubMed ID: 19627293
[TBL] [Abstract][Full Text] [Related]
12. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Rossignol P; Zannad F
Circulation; 2015 Jan; 131(1):7-10. PubMed ID: 25406307
[No Abstract] [Full Text] [Related]
13. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
Cannon JA; Shen L; Jhund PS; Anand IS; Komajda M; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2016 Aug; 18(8):1021-31. PubMed ID: 27194023
[TBL] [Abstract][Full Text] [Related]
15. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Eur J Heart Fail; 2007 May; 9(5):510-7. PubMed ID: 17317308
[TBL] [Abstract][Full Text] [Related]
17. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
[TBL] [Abstract][Full Text] [Related]
19. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.
Abdul-Rahim AH; Perez AC; Fulton RL; Jhund PS; Latini R; Tognoni G; Wikstrand J; Kjekshus J; Lip GY; Maggioni AP; Tavazzi L; Lees KR; McMurray JJ; ;
Circulation; 2015 Apr; 131(17):1486-94; discussion 1494. PubMed ID: 25810334
[TBL] [Abstract][Full Text] [Related]
20. Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Perez-Moreno AC; Jhund PS; Macdonald MR; Petrie MC; Cleland JG; Böhm M; van Veldhuisen DJ; Gullestad L; Wikstrand J; Kjekshus J; Lewsey JD; McMurray JJ
JACC Heart Fail; 2014 Apr; 2(2):187-97. PubMed ID: 24720928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
